|
Poisoning by fluorouracil
|
0.300 |
Biomarker
|
disease |
ORPHANET |
|
|
|
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].
|
15222106 |
2004 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In this study, TS and DPD gene expressions were measured in 47 primary colorectal cancer tumors and 12 metastatic tumors using FFPE specimens.
|
15222106 |
2004 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
TYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
|
15355913 |
2004 |
|
Colonic Neoplasms
|
0.360 |
Biomarker
|
group |
CTD_human |
Furthermore, four of them (one each from TYMS and PKG1 and two from AICRT/1) possessed the ability to induce HLA-A2-restricted and peptide-specific CTLs cytotoxic to colon tumor cells in peripheral blood mononuclear cells of colon cancer patients.
|
15355913 |
2004 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
|
15386371 |
2004 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
A VNTR polymorphism in the TS promoter region is associated with the efficacy of 5-FU-based chemotherapy in colorectal cancer.
|
15386371 |
2004 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
[Relationship between expression of thymidylate synthase and colorectal carcinoma].
|
15500737 |
2004 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The expression of TS is one of the important prognosis indicators of colorectal carcinoma.
|
15500737 |
2004 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
|
15837757 |
2005 |
|
Stomach Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
|
15837757 |
2005 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
|
15837757 |
2005 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.
|
15999119 |
2005 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Tissue of CaP and BPH tissue samples were obtained from formalin-fixed, paraffin-embedded sections by laser-captured microdissection, and then RNA was extracted. mRNA expression of TS, DPD, TP, and OPRT was analyzed by quantitative reverse transcriptase-polymerase chain reaction.
|
15999119 |
2005 |
|
Colorectal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
|
16141798 |
2005 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
We found that a combination of germline TS polymorphisms is an independent prognostic marker in selecting CRC patients with worse prognosis, and it may be worthwhile to examine whether these patients would benefit from an alternative therapy.
|
16141798 |
2005 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In 140 patients with primary squamous cell carcinoma (SCC) of the tongue, intratumoural TS expression was evaluated by immunohistochemistry.
|
16280240 |
2006 |
|
Tongue Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study.
|
16280240 |
2006 |
|
Malignant neoplasm of tongue
|
0.300 |
Biomarker
|
disease |
CTD_human |
The aim of this study was to assess the importance of immunohistochemical thymidylate synthase (TS) expression level as a prognostic marker in tongue cancer patients.
|
16280240 |
2006 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genotypes resulting in reduced MTHFR activity in conjunction with low TS expression were associated with a reduced risk of colon cancer.
|
16284371 |
2005 |
|
Colonic Neoplasms
|
0.360 |
Biomarker
|
group |
CTD_human |
Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer.
|
16284371 |
2005 |
|
Lymphoma, Non-Hodgkin
|
0.370 |
Biomarker
|
disease |
CTD_human |
We observed no association between NHL and haplotypes for MTHFR or TYMS.
|
16365025 |
2005 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.320 |
Biomarker
|
disease |
CTD_human |
Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes.
|
16365025 |
2005 |
|
Reticulosarcoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes.
|
16365025 |
2005 |
|
Lymphoma, Mixed-Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes.
|
16365025 |
2005 |